- Home
- KAPA vs ACXP Comparison
KAPA vs ACXP Comparison
Compare KAPA & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAPA
- ACXP
- Stock Information
- Founded
- KAPA 2013
- ACXP 2017
- Country
- KAPA United States
- ACXP United States
- Employees
- KAPA N/A
- ACXP N/A
- Industry
- KAPA
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- KAPA
- ACXP Health Care
- Exchange
- KAPA NYSE
- ACXP Nasdaq
- Market Cap
- KAPA 9.1M
- ACXP 8.4M
- IPO Year
- KAPA 2024
- ACXP 2021
- Fundamental
- Price
- KAPA $0.66
- ACXP $0.43
- Analyst Decision
- KAPA Strong Buy
- ACXP Strong Buy
- Analyst Count
- KAPA 3
- ACXP 2
- Target Price
- KAPA $8.33
- ACXP $10.00
- AVG Volume (30 Days)
- KAPA 2.2M
- ACXP 18.4M
- Earning Date
- KAPA 08-23-2025
- ACXP 08-08-2025
- Dividend Yield
- KAPA N/A
- ACXP N/A
- EPS Growth
- KAPA N/A
- ACXP N/A
- EPS
- KAPA N/A
- ACXP N/A
- Revenue
- KAPA N/A
- ACXP N/A
- Revenue This Year
- KAPA N/A
- ACXP N/A
- Revenue Next Year
- KAPA N/A
- ACXP N/A
- P/E Ratio
- KAPA N/A
- ACXP N/A
- Revenue Growth
- KAPA N/A
- ACXP N/A
- 52 Week Low
- KAPA $0.40
- ACXP $0.30
- 52 Week High
- KAPA $4.00
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- KAPA N/A
- ACXP 47.99
- Support Level
- KAPA N/A
- ACXP $0.52
- Resistance Level
- KAPA N/A
- ACXP $0.63
- Average True Range (ATR)
- KAPA 0.00
- ACXP 0.09
- MACD
- KAPA 0.00
- ACXP 0.00
- Stochastic Oscillator
- KAPA 0.00
- ACXP 17.33
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.